Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements Buchanan RW; Kreyenbuhl J; Kelly DL; Noel JM; Boggs DL; Fischer BA; Himelhoch S; Fang B; Peterson E; Aquino PR; Keller WSchizophr Bull 2010[Jan]; 36 (1): 71-93In light of the large number of studies published since the 2004 update of Schizophrenia Patient Outcomes Research Team psychopharmacological treatment recommendations, we conducted an extensive literature review to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest. We reviewed over 400 articles, which resulted in 16 treatment recommendations: the revision of 11 previous treatment recommendations and 5 new treatment recommendations. Three previous treatment recommendations were eliminated. There were 13 interventions and/or outcomes for which there was insufficient evidence for a treatment recommendation, and a statement was written to summarize the current level of evidence and identify important gaps in our knowledge that need to be addressed. In general, there was considerable consensus among the Psychopharmacology Evidence Review Group and the expert consultants. Two major areas of contention concerned whether there was sufficient evidence to recommend specific dosage ranges for the acute and maintenance treatment of first-episode and multi-episode schizophrenia and to endorse the practice of switching antipsychotics for the treatment of antipsychotic-related weight gain. Finally, there continue to be major gaps in our knowledge, including limited information on (1) the use of adjunctive pharmacological agents for the treatment of persistent positive symptoms or other symptom domains of psychopathology, including anxiety, cognitive impairments, depressive symptoms, and persistent negative symptoms and (2) the treatment of co-occurring substance or medical disorders that occur frequently in individuals with schizophrenia.|*Evidence-Based Medicine[MESH]|*Outcome Assessment, Health Care[MESH]|*Schizophrenic Psychology[MESH]|Advisory Committees[MESH]|Antipsychotic Agents/adverse effects/*therapeutic use[MESH]|Combined Modality Therapy[MESH]|Comorbidity[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Therapy, Combination[MESH]|Humans[MESH]|Psychotropic Drugs/adverse effects/therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Recurrence[MESH]|Schizophrenia/*drug therapy[MESH] |
